BR112013002504A2 - formulação farmacêutica para administração em aerosol, inalador pressurizado dosimetrado (pmdi), formulação farmacêutica para nebulização, frasco de dose única ou múltiplas e uso de uma formulação - Google Patents
formulação farmacêutica para administração em aerosol, inalador pressurizado dosimetrado (pmdi), formulação farmacêutica para nebulização, frasco de dose única ou múltiplas e uso de uma formulaçãoInfo
- Publication number
- BR112013002504A2 BR112013002504A2 BR112013002504A BR112013002504A BR112013002504A2 BR 112013002504 A2 BR112013002504 A2 BR 112013002504A2 BR 112013002504 A BR112013002504 A BR 112013002504A BR 112013002504 A BR112013002504 A BR 112013002504A BR 112013002504 A2 BR112013002504 A2 BR 112013002504A2
- Authority
- BR
- Brazil
- Prior art keywords
- formulation
- pharmaceutical
- pmdi
- misting
- multiple dose
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10171734 | 2010-08-03 | ||
| PCT/EP2011/062527 WO2012016845A2 (en) | 2010-08-03 | 2011-07-21 | Pharmaceutical formulation comprising a phosphodiesterase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112013002504A2 true BR112013002504A2 (pt) | 2016-05-31 |
Family
ID=43301924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013002504A BR112013002504A2 (pt) | 2010-08-03 | 2011-07-21 | formulação farmacêutica para administração em aerosol, inalador pressurizado dosimetrado (pmdi), formulação farmacêutica para nebulização, frasco de dose única ou múltiplas e uso de uma formulação |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9358224B2 (pt) |
| EP (2) | EP2600829B1 (pt) |
| KR (1) | KR101803121B1 (pt) |
| CN (2) | CN106377503A (pt) |
| AR (1) | AR082444A1 (pt) |
| BR (1) | BR112013002504A2 (pt) |
| CA (1) | CA2807406C (pt) |
| ES (1) | ES2628891T3 (pt) |
| RU (1) | RU2578975C2 (pt) |
| WO (1) | WO2012016845A2 (pt) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8506934B2 (en) | 2005-04-29 | 2013-08-13 | Robert I. Henkin | Methods for detection of biological substances |
| US8293489B2 (en) | 2007-01-31 | 2012-10-23 | Henkin Robert I | Methods for detection of biological substances |
| EP2022783A1 (en) | 2007-08-08 | 2009-02-11 | CHIESI FARMACEUTICI S.p.A. | "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors" |
| US8580801B2 (en) | 2008-07-23 | 2013-11-12 | Robert I. Henkin | Phosphodiesterase inhibitor treatment |
| EP2216327A1 (en) | 2009-02-06 | 2010-08-11 | CHIESI FARMACEUTICI S.p.A. | Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors |
| SG181870A1 (en) * | 2009-12-23 | 2012-07-30 | Chiesi Farma Spa | Aerosol formulation for copd |
| MX346424B (es) | 2010-08-03 | 2017-03-21 | Chiesi Farm Spa | Formulacion de polvo seco que comprende un inhibidor de fosfodiesterasa. |
| AU2012266514A1 (en) | 2011-06-06 | 2014-01-09 | Chiesi Farmaceutici S.P.A. | Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors |
| JP6434416B2 (ja) | 2012-11-08 | 2018-12-05 | ライゼン・ファーマシューティカルズ・エスアー | ＰＤＥ４阻害剤とＰＩ３δ阻害剤または二重ＰＩ３δ−γキナーゼ阻害剤とを含有する薬学的組成物 |
| CA2897464C (en) * | 2013-01-28 | 2021-05-18 | Incozen Therapeutics Pvt. Ltd. | Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast n-oxide |
| ES2744542T3 (es) * | 2013-03-15 | 2020-02-25 | Robert I Henkin | Inhibidores de fosfodiesterasa para tratar trastornos gustativos y olfativos |
| CN105658629B (zh) | 2013-10-22 | 2019-07-16 | 奇斯药制品公司 | 用于制备pde4抑制剂的方法 |
| US10598672B2 (en) | 2014-02-18 | 2020-03-24 | Cyrano Therapeutics, Inc. | Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell |
| WO2017089347A1 (en) | 2015-11-25 | 2017-06-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas |
| CA3165307A1 (en) * | 2020-02-20 | 2021-08-26 | Enrico Zambelli | Pressurised metered dose inhalers comprising a buffered pharmaceutical formulation |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8828477D0 (en) * | 1988-12-06 | 1989-01-05 | Riker Laboratories Inc | Medical aerosol formulations |
| IT1303788B1 (it) * | 1998-11-25 | 2001-02-23 | Chiesi Farma Spa | Formulazioni di aerosol medicinali. |
| SE0200312D0 (sv) * | 2002-02-01 | 2002-02-01 | Astrazeneca Ab | Novel composition |
| DE10205087A1 (de) * | 2002-02-07 | 2003-08-21 | Pharmatech Gmbh | Cyclodextrine als Suspensionsstabilisatoren in druckverflüssigten Treibmitteln |
| US20100129363A1 (en) * | 2002-05-17 | 2010-05-27 | Zeldis Jerome B | Methods and compositions using pde4 inhibitors for the treatment and management of cancers |
| DE602006014139D1 (de) * | 2005-06-06 | 2010-06-17 | Hoffmann La Roche | Sulfonamid-derivate als lebercarnitin-palmitoyl-transferase-hemmer |
| US20070286814A1 (en) * | 2006-06-12 | 2007-12-13 | Medispray Laboratories Pvt. Ltd. | Stable aerosol pharmaceutical formulations |
| WO2008006509A1 (en) | 2006-07-14 | 2008-01-17 | Chiesi Farmaceutici S.P.A. | Derivatives of 1-phenyl-2-pyridynyl alkylene alcohols as phosphodiesterase inhibitors |
| EP2022783A1 (en) | 2007-08-08 | 2009-02-11 | CHIESI FARMACEUTICI S.p.A. | "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors" |
| EP2070913A1 (en) * | 2007-12-14 | 2009-06-17 | CHIESI FARMACEUTICI S.p.A. | Ester derivatives as phosphodiesterase inhibitors |
| EP2110375A1 (en) | 2008-04-14 | 2009-10-21 | CHIESI FARMACEUTICI S.p.A. | Phosphodiesterase-4 inhibitors belonging to the tertiary amine class |
| EP2216327A1 (en) * | 2009-02-06 | 2010-08-11 | CHIESI FARMACEUTICI S.p.A. | Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors |
| MX346424B (es) | 2010-08-03 | 2017-03-21 | Chiesi Farm Spa | Formulacion de polvo seco que comprende un inhibidor de fosfodiesterasa. |
-
2011
- 2011-07-21 CN CN201611021810.0A patent/CN106377503A/zh active Pending
- 2011-07-21 CN CN2011800378895A patent/CN103052378A/zh active Pending
- 2011-07-21 EP EP11740611.6A patent/EP2600829B1/en active Active
- 2011-07-21 CA CA2807406A patent/CA2807406C/en active Active
- 2011-07-21 WO PCT/EP2011/062527 patent/WO2012016845A2/en active Application Filing
- 2011-07-21 KR KR1020137002732A patent/KR101803121B1/ko active IP Right Grant
- 2011-07-21 EP EP16190948.6A patent/EP3143987A1/en not_active Withdrawn
- 2011-07-21 ES ES11740611.6T patent/ES2628891T3/es active Active
- 2011-07-21 BR BR112013002504A patent/BR112013002504A2/pt not_active Application Discontinuation
- 2011-07-21 RU RU2013104401/15A patent/RU2578975C2/ru active
- 2011-08-02 US US13/195,903 patent/US9358224B2/en active Active
- 2011-08-02 AR ARP110102783A patent/AR082444A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| RU2578975C2 (ru) | 2016-03-27 |
| CA2807406A1 (en) | 2012-02-09 |
| WO2012016845A3 (en) | 2012-04-12 |
| RU2013104401A (ru) | 2014-08-10 |
| WO2012016845A2 (en) | 2012-02-09 |
| KR101803121B1 (ko) | 2017-11-29 |
| ES2628891T3 (es) | 2017-08-04 |
| CN103052378A (zh) | 2013-04-17 |
| CN106377503A (zh) | 2017-02-08 |
| EP3143987A1 (en) | 2017-03-22 |
| EP2600829B1 (en) | 2017-06-14 |
| CA2807406C (en) | 2018-12-11 |
| AR082444A1 (es) | 2012-12-05 |
| US20120034172A1 (en) | 2012-02-09 |
| US9358224B2 (en) | 2016-06-07 |
| KR20130094782A (ko) | 2013-08-26 |
| EP2600829A2 (en) | 2013-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112013002504A2 (pt) | formulação farmacêutica para administração em aerosol, inalador pressurizado dosimetrado (pmdi), formulação farmacêutica para nebulização, frasco de dose única ou múltiplas e uso de uma formulação | |
| DK2010190T3 (da) | Farmaceutisk opløsningsformulering til tryksatte, dosisregulerede inhalatorer | |
| BR112013028572A2 (pt) | bocais para entrega de droga nasal | |
| HRP20181550T1 (hr) | Formulacija suhog praška koja sadrži kortikosteroid i beta-adrenergik za davanje inhalacijom | |
| EP2647380A4 (en) | PHARMACEUTICAL COMPOSITION WITH MOMETASON FUROAT AND AZELASTINE HYDROCHLORIDE FOR NASAL ADMINISTRATION | |
| BR112012032330A2 (pt) | formulação em pó seco inalável, uso de uma formulação em pó seco, inalador de pó seco e embalagem | |
| WO2013114371A8 (en) | Dry powder formulations of dnase i | |
| BRPI0507225A2 (pt) | formulações estáveis de solução farmacêutica para inaladores pressurizados de dose medida | |
| WO2013104892A8 (en) | Application of high dose compounds via inhalation | |
| HK1200337A1 (en) | Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof | |
| ZA202007890B (en) | Stable pharmaceutical compositions for pressurized metered dose inhalers | |
| BR112013017570A2 (pt) | compostos de pirazola como antagonistas de crth2 | |
| JO3024B1 (ar) | صيغ أيروسول صيدلانية من الفرموتيرول وبكلوميتازون داي بروبيونات | |
| BR112013008302A2 (pt) | composto, composição farmacêutica contendo o mesmo e uso do referido composto na preparação de um medicamento | |
| BR112014008114A2 (pt) | micropartículas cristalinas, formulação farmacêutica, inalador dosimetrado pressurizado, formulação farmacêutica, processo para preparar microparticulas cristalinas e uso de micropartículas cristalinas | |
| IL226344A (en) | History of imidazole, their use in the preparation of pharmaceuticals and pharmaceuticals containing them |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |